3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
32
Breast Neoplasms
25
Parkinson Disease 4, Autosomal Dominant Lewy Body
18
Multiple Myeloma
13
Neoplasms
12
Leukemia, Myeloid, Acute
12
Ovarian Neoplasms
10
Neoplasm Metastasis
10
Leukemia, Lymphocytic, Chronic, B-Cell
10
Carcinoma, Renal Cell
9
Prostatic Neoplasms
8
Colorectal Neoplasms
8
Melanoma
7
Lymphoma, Non-Hodgkin
7
Leukemia
7
Stomach Neoplasms
6
Recurrence
6
Fallopian Tube Neoplasms
6
Carcinoma, Hepatocellular
6
Carcinoma
6
Urinary Bladder Neoplasms
5
Small Cell Lung Carcinoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma
5
Adenocarcinoma
5
Purpura, Thrombocytopenic, Idiopathic
4
Myelodysplastic Syndromes
4
Lymphoma, Follicular
4
Liver Neoplasms
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Interventions
Everolimus
1
Anticonvulsants
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Has announcements
×
Tuberous Sclerosis Complex-associated Refractory Seizures
×
Clear all
NCT01713946
2018-11-07
EXIST-3
Novartis
Phase 3
Completed
366 enrolled
38 charts
1 FDA